BCAX
Bicara Therapeutics Inc.
Latest Form 4:Sale$350KbyHyep Ivan (Chief Financial Officer) · filed Aug 12, 2026
Bicara Therapeutics Inc. (BCAX) has 45 SEC Form 4 filings (131 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Aug 12, 2026.
The most active filer is Chief Financial Officer Hyep Ivan with 15 filings. Insiders have net sold $2.6M over the trailing 6 months. The largest single insider purchase in this window was $4.8M by Director, 10% Owner RA CAPITAL MANAGEMENT, L.P. on Feb 26, 2026.
- Industry:Biotechnology
- CEO:Claire Mazumdar Clemon
- Employees:103
- HQ:Boston, MA, US
- IPO:2024-09-13
Insider Buying
$4.8M
reported purchases (SEC code P)
Insider Selling
$13.3M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Market Cap
$1.5B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Financial Officer | Sale | 12,500 | $350K | Aug 12 | SEC ↗ | |
| President and COO | Sale | 18,750 | $525K | Aug 12 | SEC ↗ | |
| Chief Executive Officer | Sale | 10,000 | $280K | Aug 12 | SEC ↗ | |
| Chief Executive Officer | Sale | 10,000 | $284K | Jul 14 | SEC ↗ | |
| Chief Financial Officer | Sale | 28,000 | $808K | Jul 10 | SEC ↗ | |
| President and COO | Sale | 28,214 | $818K | Jul 10 | SEC ↗ | |
| President and COO | Sale | 536 | $16K | Jul 10 | SEC ↗ | |
| Chief Financial Officer | Sale | 9,200 | $188K | May 26 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $301K | May 20 | SEC ↗ | |
| President and COO | Sale | 12,500 | $254K | May 18 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $126K | Apr 28 | SEC ↗ | |
| Chief Financial Officer | Sale | 9,200 | $212K | Apr 22 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $354K | Apr 20 | SEC ↗ | |
| President and COO | Sale | 12,500 | $288K | Apr 17 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $104K | Mar 26 | SEC ↗ | |
| Chief Financial Officer | Sale | 9,200 | $170K | Mar 24 | SEC ↗ | |
| Chief Executive Officer | Sale | 6,499 | $122K | Mar 20 | SEC ↗ | |
| Chief Executive Officer | Sale | 6,905 | $130K | Mar 20 | SEC ↗ | |
| Chief Executive Officer | Sale | 1,596 | $30K | Mar 20 | SEC ↗ | |
| President and COO | Sale | 12,500 | $246K | Mar 17 | SEC ↗ | |
| Chief Executive Officer | Sale | 36,766 | $705K | Mar 11 | SEC ↗ | |
Mazumdar ClaireFirst in 3 months | Chief Executive Officer | Sale | 2,631 | $49K | Mar 6 | SEC ↗ |
Mazumdar ClaireFirst in 3 months | Chief Executive Officer | Sale | 1,786 | $33K | Mar 6 | SEC ↗ |
Mazumdar ClaireFirst in 3 months | Chief Executive Officer | Sale | 3,817 | $72K | Mar 6 | SEC ↗ |
| Chief Financial Officer | Sale | 13,555 | $247K | Mar 5 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,963 | $54K | Mar 5 | SEC ↗ | |
Raben DavidFirst in 3 months | Chief Medical Officer | Sale | 200 | $4K | Mar 5 | SEC ↗ |
Raben DavidFirst in 3 months | Chief Medical Officer | Sale | 16,300 | $302K | Mar 5 | SEC ↗ |
| President and COO | Sale | 17,392 | $316K | Mar 5 | SEC ↗ | |
| Director, 10% Owner | Purchase | 300,000 | $4.8M | Mar 2 | SEC ↗ | |
| President and COO | Sale | 3,631 | $66K | Feb 27 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,882 | $34K | Jan 26 | SEC ↗ | |
| President and COO | Sale | 3,828 | $69K | Jan 26 | SEC ↗ | |
| President and COO | Sale | 149 | $3K | Jan 20 | SEC ↗ | |
| Chief Financial Officer | Sale | 9,200 | $168K | Dec 23 | SEC ↗ | |
| President and COO | Sale | 12,500 | $234K | Dec 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $101K | Nov 25 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $104K | Nov 25 | SEC ↗ | |
| Chief Financial Officer | Sale | 605 | $11K | Nov 25 | SEC ↗ | |
| Chief Financial Officer | Sale | 17,795 | $330K | Nov 25 | SEC ↗ | |
| Chief Executive Officer | Sale | 41,163 | $776K | Nov 25 | SEC ↗ | |
| President and COO | Sale | 12,500 | $226K | Nov 25 | SEC ↗ | |
| Chief Executive Officer | Sale | 24,103 | $454K | Oct 20 | SEC ↗ | |
| President and COO | Sale | 12,500 | $227K | Oct 16 | SEC ↗ | |
Mazumdar ClaireFirst filing | Chief Executive Officer | Sale | 11,445 | $217K | Oct 15 | SEC ↗ |
Mazumdar ClaireFirst filing | Chief Executive Officer | Sale | 13,289 | $250K | Oct 15 | SEC ↗ |
| Chief Financial Officer | Sale | 6,415 | $117K | Oct 10 | SEC ↗ | |
Raben DavidFirst filing | Chief Medical Officer | Sale | 22,000 | $406K | Oct 10 | SEC ↗ |
Hyep IvanFirst filing | Chief Financial Officer | Sale | 6,514 | $118K | Oct 8 | SEC ↗ |
Hyep IvanFirst filing | Chief Financial Officer | Sale | 18,244 | $332K | Oct 8 | SEC ↗ |
Hyep IvanFirst filing | Chief Financial Officer | Sale | 5,627 | $102K | Oct 8 | SEC ↗ |
Cohlhepp RyanFirst filing | President and COO | Sale | 39,600 | $715K | Oct 8 | SEC ↗ |
Cohlhepp RyanFirst filing | President and COO | Sale | 10,900 | $197K | Oct 8 | SEC ↗ |
| Chief Legal Officer | Sale | 33,807 | $499K | Oct 1 | SEC ↗ | |
Meisner LaraFirst filing | Chief Legal Officer | Sale | 15,829 | $182K | Sep 17 | SEC ↗ |
Related companies
Bicara Therapeutics Inc. is in the Healthcare sector.